International Journal of Medical and Health Research

Authors
Imad A AlJahdaly, Mohammad M Alkot, Hossam S Abdelbaki, Fares F Zafrani, Fahad M Alkhuzaei, Samah M Al-Qurashi, Waad A Almjnouni, Doaa M Ghazna, Fatimah N AlShaikh Ahmed

Abstract
Background: Mastalgia can be defined as “breast pain sufficient for medical consultation. Although mastalgia remains an under-reported and poorly recognized illness, it is the most frequent reason for breast consultations in family practice. Breast pain is recently classified into: cyclic mastalgia, non-cyclic mastalgia, and non-breast chest pain. Despite of wide varieties of regimens for management of cyclic mastalgia, there is no standard one. General objective of the study: was promotion of adolescent health and the specific one was evaluation of the effectiveness of progesterone pills versus placebo on reducing the pain of cyclic mastalgia and minimizing its impact on education, daily activities, sleep and quality of life. Methods: Two hundred and twenty three adolescent females (aged 14-18 years) with cyclic mastalgia 6 months before conduction of the study were recruited to a randomized, double-blind, placebo-controlled, clinical trial. Eligible patients were randomly assigned after their consent into two groups. Patients in the intervention group received progesterone pills for 6 menstrual cycles. Patients in the placebo group took placebo in a similar way. Breast pain, tenderness, nodularity and impact of pain on lifestyle parameters were assessed before, during and after the intervention based on patients’ daily self-assessment using the Visual Analogue Scale. Results: Severity of mastalgia and its impact on education, daily activities, sleep and quality of life pre and post trail in each individual group and in-between the groups were statistically insignificant (P>0.05). Development of adverse reaction were significantly much higher among progesterone versus placebo group (P<0.001) such as headache (19.1% vs.5.6%), appetite changes (16.2% vs.2.8%), acne (17.6% vs.10.8%), and mood swings (14.7% vs.2.1%). Conclusion: Progesterone have no superiority over placebo in reducing the cyclic mastalgia rather than it induce a variety of adverse reactions